Accium BioSciences

Accium BioSciences

  • 1600 E Jefferson St Ste 501
  • Seattle, Washington
  • 98122

Website Links

Description

Dr. Kawasaki has 24 years of experience in start-up biotechnology companies. He was the first scientist (1981) and chair of the Science Board at ZymoGenetics, Inc., today a one-billion-dollar public corporation. He has a Ph.D. in Genetics (1979), an M.B.A. (1986), and a J.D. (1995) each from the University of Washington. Dr. Kawasaki was a research fellow at Harvard Medical School from 1979-81 and was an undergraduate at U.C. Berkeley, where he earned a B.S. in Genetics and an A.B. in Zoology. In 1989 he founded Aptein, Inc., which was based on Dr.

Julie Zalikowski joined Accium in late 2012, bringing with her over 15 years of experience within the pharmaceutical bioanalytical industry, including leadership positions at Amgen, Novartis Diagnostics and AstraZeneca. Julie's DMPK experience covers a wide range of activities, from small molecule development at AstraZeneca-Wilmington, which included development of Crestor, to large molecule development and CRO management at Amgen-Seattle. In addition to her strong analytical and scientific skills, Julie has considerable experience in project management.

Our experienced Study Directors bring years of experience designing customized protocols for a range of AMS based studies. The staff produce detailed Bioanalytical Protocols based on a collaborative relationship with our customers and are directly responsible for the day-to-day conduct of the procedures.

Accium has successfully delivered on a wide range of AMS-based mass balance studies. Each study was customized to address particular challenges that were specific to each program. In particular, we provide real-time processing and analysis of fecal samples and submit QC’d results to the clinic to support discharge decisions.

We are a leading provider of GLP/GCP compliant accelerator mass spectrometry (AMS) services to the global pharmaceutical and life science industries. Our customers use AMS services to overcome challenges they face in drug development, including assessment of pharmacokinetics, metabolism and mass balance.

Company contacts

  • Barbara Alford-cassel
  • Vice President

Products & services

Similar companies nearby